Provet Cloud vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Information Management System
Cloud-based veterinary information management system acquired by Nordhealth; Helsinki Finland; serves 3,000+ clinics across Europe, Australia, New Zealand, and North America;
About
Provet Cloud is a cloud-based veterinary information management system (VIMS) that provides veterinary practices with patient records, appointment scheduling, invoicing, pharmacy management, lab integration, and reporting in a browser-accessible platform, developed and headquartered in Helsinki, Finland and acquired by Nordhealth, the Nordic health technology group. Provet Cloud serves more than 3,000 veterinary clinics across Europe, Australia, New Zealand, and North America, making it one of the most internationally deployed cloud-native veterinary practice management platforms available.\n\nProvet Cloud's platform is designed for general veterinary practices, emergency clinics, and specialty hospitals, offering a clinical workflow that tracks patients from check-in through consultation, diagnostics, treatment, and discharge with integrated invoicing and payment collection. Lab integrations connect directly to in-house analyzers and external diagnostic labs, bringing results into the patient record automatically. The platform's multi-location and multi-user architecture supports corporate veterinary groups and franchise networks that need consolidated reporting across clinics while maintaining individual clinic workflows. APIs allow integration with third-party diagnostic, imaging, and practice growth tools.\n\nAs part of Nordhealth, Provet Cloud benefits from investment in development resources and synergies with Nordhealth's other healthcare technology platforms. Provet Cloud competes with ezyVet (owned by IDEXX), Digitail, Vetspire, and the legacy PIMS offerings from IDEXX and Henry Schein. Its strong presence in European and Australasian markets differentiates it from US-centric competitors, and its API-first architecture appeals to technology-forward practices and corporate groups building integrated technology stacks.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.